UK Medicines and Healthcare Products Regulatory Agency has Validated and Accepted the Marketing Authorization Application for ADL-018, a Proposed Biosimilar of Xolair® (omalizumab)

Contributed by: Business Wire

Tags

Science

Biotechnology

Research

Pharmaceutical

Managed Care

General Health

Health

Clinical Trials

Kashiv BioSciences, LLC

More Like This

Celltrion receives European Commission approval of Omlyclo® (CT-P39), the first and only omalizumab biosimilar approved in Europe

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)

Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars

Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress

Celltrion Receives Positive CHMP Opinion for Three Biosimilars in the European Union

Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis

Stapokibart Was Granted Marketing Approval From National Medical Products Administration For The Treatment Of Moderate-to-severe Atopic Dermatitis in Adults

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14